Author: claimsbot

1. Child’s clock indicator comprising:
a housing containing time-switch or timepiece elements;
a window displaying a stationary screen having two designs formed thereon, a first design representing a waking position and a second design representing a sleeping position;
a first set of light elements associated with the first design and a second set of light elements associated with the second design;
timing adjustment controls which allow setting a light elements switching time;
wherein the child’s clock indicator further comprises at least one switching element configured to switch on the first set of light elements and to switch off the second set of light elements indicating to a child that he may get up, said at least one switching element being further configured to switch off the first set of light elements and to switch on the second set of light elements indicating to a child that he must stay in bed;
wherein the timing adjustment control allows to set a first time at which said first set of light elements is switched on and said second set of light elements is switched off, said first time corresponding to a morning waking time;
wherein the timing adjustment control allows to set at least one second time at which said first set of light elements is switched off and said second set of light elements is switched on, said at least one second time corresponding to the time of a beginning of a nap;
wherein the timing adjustment control allows to set at least one third time at which said first set of light elements is switched on and said second set of light elements is switched off, said at least one third time corresponding to the time of an end of a nap; and
wherein said first time, said at least one second time and said at least one third time can all be set before the first time arrives.
2. Child’s clock indicator according to claim 1, wherein the first design is a standing-up position and the second design is a lying-down position.
3. Clock indicator according to claim 1, wherein the first design is a sun shape and the second design is a moon shape.
4. Child’s clock indicator according to claim 1, wherein the waking position and the sleeping position have different colors.
5. Child’s clock indicator according to claim 1, wherein the screen is made from liquid crystal elements.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An image processing apparatus comprising:
plural trays;
a reading section configured to convert an image formed on a sheet into image data and cause a storing section to store the image data;
an erasing section configured to erase the image formed on the sheet; and
a control section configured to acquire the image data from the storing section, determine, using the image data, whether a trace of a staple is present on the sheet, and convey the sheet, from which the image is erased by the erasing section, to any one of the plural trays such that a conveying destination is different according to a determination result.
2. The apparatus according to claim 1, wherein, if the control section determines that a trace of a staple is present on the sheet, the control section performs control to convey the sheet, from which the image is erased by the erasing section, to a first tray among the plural trays and, if the control section determines that a trace of a staple is absent, the control section performs control to convey the sheet, from which the image is erased, to a second tray different from the first tray.
3. The apparatus according to claim 2, where the control section further acquires, if printing processing is performed by reusing the sheet, setting information concerning whether a staple is attached to the sheet after printing and, if the setting information is information indicating that a staple is attached, performs control to feed a sheet from the second tray.
4. The apparatus according to claim 3, wherein, if the setting information is information indicating that a staple is not attached, the control section performs control to feed a sheet from the first tray or a tray in which new sheets are stored.
5. The apparatus according to claim 3, wherein the control section further acquires the setting information and information concerning a position where a staple is attached and, if the setting information is information indicating that a staple is attached and the position information and a position of a staple trace of a sheet stored in the first tray are different, performs control to feed a sheet from the first tray.
6. The apparatus according to claim 5, wherein, if the setting information is information indicating that a staple is attached and the position information and the position of the staple trace of the sheet stored in the first tray are the same, the control section performs control to feed a sheet from the second tray or a tray in which new sheets are stored.
7. The apparatus according to claim 2, further comprising a sheet reversing mechanism configured to reverse a surface of a sheet, wherein
the control further specifies, if a trace of a staple is present, a position of the staple trace from the image data and, if the specified position is a reversed position of a predetermined position, after the sheet reversing mechanism reverses the sheet, conveys the sheet to the first tray.
8. The apparatus according to claim 1, wherein the control section further acquires the image data from the storing section, acquires a paper pattern of a predetermined region of the image data, and conveys the sheet, from which the image is erased by the erasing section, to any one of the plural trays on the basis of information concerning the paper pattern.
9. The apparatus according to claim 8, wherein
the control section causes the storing section to store in advance a table in which paper pattern information and a number of times of erasing for a sheet are associated with each other, retrieves, from the table, paper pattern information same as paper pattern information of a sheet read by the reading section, acquires a number of times of erasing of the paper pattern information, and, if the number of times of erasing exceeds a predetermined value, conveys the sheet to a tray for disposal among the plural trays.
10. The apparatus according to claim 8, wherein
the control section further causes the storing section to store in advance a table in which paper pattern information and a number of times of stapling counted for each position in a sheet are associated with each other, acquires the number of times of stapling from the table using paper pattern information of a sheet read by the reading section and a position of a staple trace drawn on the image data, if the number of times of stapling exceeds a specified value, conveys the sheet to a first tray in which sheets for which a staple cannot be used during next printing are stored, and, if the number of times of stapling does not exceed the specified value, conveys the sheet to a second tray in which sheets for which a staple can be used during the next printing are stored.
11. The apparatus according to claim 1, wherein, if the control section further determines that a trace of a staple is present on the sheet, the control section specifies a position of a staple trace drawn on the image data and performs control to convey the sheet to any one of the plural tray according to the position.
12. The apparatus according to claim 1, wherein
the reading section reads a front side and a rear side of a sheet and causes the storing section to store image data of the front side and the rear side,
the control section further determines, using the image data of the front side and the rear side stored in the storing section, on which side of the sheet an image is formed, and
the erasing section erases, on the basis of a determination result of the control section, the image on one of the front side and the rear side or both the sides.
13. A method of diverting sheets via an image processing apparatus, the method comprising:
converting an image formed on a sheet into image data and causing a storing section to store the image data;
erasing the image formed on the sheet; and
acquiring the image data from the storing section, determining, using the image data, whether a trace of a staple is present on the sheet, and conveying the sheet, from which the image is erased, to any one of plural trays such that a conveying destination is different according to a determination result.
14. The method according to claim 13, wherein, if a trace of a staple is present on the sheet, conveying the sheet, from which the image is erased, to a first tray among the plural trays and, if a trace of a staple is absent, conveying the sheet, from which the image is erased, to a second tray different from the first tray.
15. The method according to claim 14, further acquiring, if printing processing is performed by reusing the sheet, setting information concerning whether a staple is attached to the sheet after printing and, if the setting information is information indicating that a staple is attached, feeding a sheet from the second tray.
16. The method according to claim 15, wherein, if the setting information is information indicating that a staple is not attached, feeding a sheet from the first tray or a tray in which new sheets are stored.
17. The method according to claim 15, further acquiring the setting information and information concerning a position where a staple is attached and, if the setting information is information indicating that a staple is attached and the position information and a position of a staple trace of a sheet stored in the first tray are different, feeding a sheet from the first tray.
18. The method according to claim 17, wherein, if the setting information is information indicating that a staple is attached and the position information and the position of the staple trace of the sheet stored in the first tray are the same, feeding a sheet from the second tray or a tray in which new sheets are stored.
19. The method according to claim 13, further acquiring the image data from the storing section, acquiring a paper pattern of a predetermined region of the image data, and conveying the sheet, from which the image is erased, to any one of the plural trays on the basis of information concerning the paper pattern.
20. The method according to claim 19, further causing the storing section to store in advance a table in which paper pattern information and a number of times of erasing for a sheet are associated with each other, retrieving, from the table, paper pattern information same as paper pattern information of a sheet read, acquiring a number of times of erasing of the paper pattern information, and, if the number of times of erasing exceeds a predetermined value, conveying the sheet to a tray for disposal among the plural trays.

1. A compound of Formula I
wherein
n is 0, 1, 2, or 3;
m is 0, 1, 2, or 3;
p is 1 or 2;
q is 0, 1, 2, 3, or 4;
Y is a bond, C\u2550O, or S(O)t; wherein t is 0, 1, or 2;
R1 is selected from a group consisting of: hydroxy, C1-C6 alkyl, aryl, C2-C6 alkenyl, C1-C6 haloalkyl, C1-C6 alkylheterocyclic, C3-C8 cycloalkyl, C1-C6 alkylcycloalkyl; C1-C6 alkylaryl, heterocyclyl, C1-C6 alkylalcohol, C1-C6 alkoxy, aryloxy, \u2014OC2-C6 alkenyl, \u2014OC1-C6 haloalkyl, \u2014OC1-C6 alkylheterocyclic, \u2014OC3-C8 cycloalkyl, \u2014OC1-C6 alkylcycloalkyl, \u2014NR7R8 and \u2014OC1-C6 alkylaryl, \u2014O-heterocyclic, \u2014OC1-C6 alkylheterocyclic, CI-C6 alkyl-O\u2014C(O)NR7R8, C1-C6 alkyl-NR7C(O)NR7R8, and C0-C6 alkylCOOR11; provided that R1 is not hydroxy when Y is S(O)t; and wherein each cycloalkyl, aryl and heterocyclic group is optionally substituted with 1 to 3 groups independently selected from oxo, hydroxy, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 alkylalcohol, CONR11R12, NR11SO2R12, NR11COR12, C0-C3 alkylNR11R12, C1-C3 alkylCOR11, C0-C6 alkylCOOR11, cyano, C1-C6 alkylcycloalkyl, phenyl, \u2014OC1-C6 alkylcycloalkyl, \u2014OC1-C6 alkylaryl, \u2014OC1-C6 alkylheterocyclic, and C1-C6 alkylaryl;
each R2 is bound only to a carbon atom and is a group independently selected from the group consisting of: hydrogen, hydroxy, halogen, oxo, C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C1-C6 haloalkyl, CONR11R12, \u2014NR11SO2R12, \u2014NR11COR12, C0-C6 alkylNR11R12, C0-C6 alkylCOR1, C0-C6 alkylCOOR11, cyano, nitro, C0-C6 alkylcycloalkyl, phenyl, C0-C6 alkylaryl, heterocyclyl, C3-C8 cycloalkyl, and C1-C6 haloalkyl; and wherein two independently selected R2 groups are optionally gem-disubstituted;
R3a and R3b are independently selected from the group consisting of: hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, and C1-C6 haloalkyl;
R4 is a group represented by the formula \u2014NR4aR4b wherein;
R4a is a heterocyclic, C1-C6 alkylheterocyclic, or C2-C6 alkenylheterocyclic group wherein each heterocyclic group is optionally substituted with 1 to 3 groups independently selected from the group consisting of: oxo, hydroxyl, halogen, \u2014NR11R12, C1-C6 alkyl, C1-C6 alkenyl, C0-C6 alkylCN, C1-C6 alkoxy, C1-C6 alkylalcohol, C1-C6 haloalkyl, \u2014OC(O)NR11R12, C1-C6 alkylNR11R12 wherein the C1-C6 alkyl group is optionally substituted with \u2014OR10 or C(O)OR10, C0-C6 alkylNO2, C0-C6 alkylNR11SO2R12, C0-C6 alkylC(O)NR11R12, C0-C6 alkylNR11C(O)R12, C0-C6 alkylNR11C(O)OR12, C0-C6 alkylNR11C(O)NR10R12, C0-C6 alkylNR11CHR10CO2R12, C0-C6 alkylC(O)OR11, C0-C6 alkylSO2NR11R12, C0-C6 alkylS(O)tR11, C3-C8 cycloalkyl, C1-C6 alkylcycloalkyl, and C0-C6 alkylheterocyclic wherein the heterocycle of the C0-C6 alkylheterocyclic group is optionally substituted with halo, C1-C6 alkyl, oxo, \u2014CO2R11 and \u2014NR11R12; and
R4b is selected from the group consisting of: C1-C6 alkylaryl, C2-C6 alkenylaryl, C2-C6 alkynylaryl, C1-C6 alkylheterocyclic, C2-C6 alkenylheterocyclic, C1-C6 alkylcycloalkyl, C1-C6 alkyl-O\u2014C1-C6 alkylaryl, wherein each cycloalkyl, aryl, or heterocyclic group is optionally substituted with 1-3 groups independently selected from the group consisting of:

hydroxy, oxo, \u2014SC1-C6 alkyl, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 haloalkyl, halogen, C1-C6 alkoxy, aryloxy, C1-C6 alkenyloxy, C1-C6 haloalkoxyalkyl, C0-C6 alkylNR11R12, \u2014OC1-C6 alkylaryl, nitro, cyano, C1-C6 haloalkylalcohol, and C1-C6 alkyl alcohol;
R5 is selected from a group consisting of: hydrogen, hydroxy, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, aryloxy, \u2014OC2-C6 alkenyl, \u2014OC1-C6 haloalkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, C1-C6 alkylaryl, C1-C6 alkylheterocyclic, C2-C6 alkenylaryl, C2-C6 alkenylheterocyclic, aryl, heterocyclic, cyano, nitro, C0-C6 alkylNR7R8, C0-C6 alkylCOR7, C0-C6 alkylCO2R7, C0-C6 alkylCONR7R8, CONR7SO2R8, \u2014NR7SO2R8, \u2014NR7COR8, \u2014N\u2550CR7R8, \u2014OCONR7R8, \u2014S(O)tR7, \u2014SO2NR7R8, C0-C5CH2OH, \u2014OC1-C6 alkylheterocyclic, and \u2014OC1-C6 alkylaryl wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heterocyclic group or subgroup is optionally substituted with oxo, alkyloxy, aryloxy; and wherein any two R5 groups may combine to form an optionally substituted 5, 6, or 7-member fused ring with the phenyl ring (A-ring) to which they are attached, wherein the 5, 6, or 7-member fused ring is saturated, partially unsaturated, or fully unsaturated and optionally contains 1, 2, or 3 heteroatoms independently selected from O, N, and S;
R6 is independently selected from a group consisting of: hydrogen, C1-C6 alkyl, C2-C6 alkenyl, hydroxy, COR7, C1-C6 alkoxy, aryloxy, \u2014OC2-C6 alkenyl, \u2014OC1-C6 haloalkyl, C1-C6 alkylNR7R8, C3-C8 cycloalkyl, heterocyclic, aryl, C1-C6 alkyl-O\u2014C(O)NR7R8, C1-C6 alkyl-NR7C(O)NR7R8 and C1-C6 alkylcycloalkyl;
R7 and R8 are each independently selected from a group consisting of: hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, \u2014OC1-C6 alkyl, C1-C6 haloalkyl, \u2014O-aryl, \u2014OC3-C8 cycloalkyl, \u2014O-heterocyclic, \u2014NR7R8, \u2014C1-C6 alkylcycloalkyl, \u2014OC1-C6 alkylcycloalkyl, \u2014OC1-C6 alkylheterocyclic, C1-C6 alkylheterocyclic, \u2014O C1-C6 alkylaryl, C3-C8 cycloalkyl, heterocyclic, aryl, and C1-C6 alkylaryl, wherein each alkyl, cycloalkyl, heterocyclic or aryl group is optionally substituted with 1-3 groups independently selected from hydroxy, CN, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and \u2014NR11R12, or R7 and R8 combine to form a nitrogen containing heterocyclic ring which having 0, 1, or 2 additional heteroatoms selected from oxygen, nitrogen and sulfur and wherein the nitrogen-containing heterocycle is optionally substituted with oxo or C1-C6 alkyl;
R10, R11 and R12 are independently selected from a group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C3-C8 cycloalkyl, heterocyclic, aryl, C1-C6 alkylaryl, wherein each alkyl, aryl, cycloalkyl, and heterocyclic group is optionally substituted with 1-3 groups independently selected from halogen, C1-C6 alkylheterocyclic, and C1-C6 haloalkyl, or R11 and R12 combine to form a nitrogen containing heterocyclic ring which may have 0, 1, or 2 additional heteroatoms selected from oxygen, nitrogen or sulfur and is optionally substituted with oxo, C1-C6 alkyl, COR7, and \u2014SO2R7;
or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture of diastereomers thereof.
2. A compound of claim 1 wherein p is 1.
3. A compound according to claim 1 wherein n, m, and q are independently 0, or 1.
4. A compound according to claim 1 wherein p is 1, n is 0, Y is C(O), and R1 is selected from a group consisting of: hydroxy, hydrogen, C1-C6 alkyl, C0-C6 alkylcycloalkyl, C0-C6 alkylheterocyclic, C1-C6 haloalkyl, C0-C6 alkylaryl, \u2014Oaryl, \u2014OC1-C6 haloalkyl, \u2014OC1-C6 alkylcycloalkyl, \u2014OC3-C8 cycloalkyl, \u2014OC1-C6 alkylcycloalkylNR7R8, \u2014OC1-C6 alkyl, \u2014OC0-C6 alkylaryl, \u2014OC1-C6 alkylcyano, \u2014OC1-C6 alkylCO2R11, \u2014OC3-C8 cycloalkylCO2R11, \u2014OC1-C6 alkylhydroxy, \u2014OC1-C6 alkylNR7R8 and \u2014OC1-C6 alkylheterocyclic; and wherein each alkyl, cycloalkyl, aryl, or heterocyclic is optionally substituted with 1 or 2 groups selected from halogen, C0-C3 alkylalcohol, C0-C3 alkylamine, C0-C3 alkylCOOH, C0-C3 alkylCONH2, C0-C3 alkylcyano, and
C0-C3 alkylC(O)OC1-C3 alkyl.
5. A compound according to claim 1 wherein p is 1, n is 0, Y is a bond, and R1 is selected from a group consisting of: C1-C6 alkyl, C0-C6 alkylcycloalkyl, C1-C6 alkylheterocyclic, C2-C6 haloalkyl, C0-C6 alkylaryl, C1-C6 alkylcycloalkylNR7R8, C1-C6 alkylcyano, C1-C6 alkylCO2R11, C1-C6 alkylcycloalkylCO2R11, C1-C6 alkylalcohol, and C1-C6 alkylNR7R8; and wherein each alkyl, cycloalkyl, aryl, or heterocyclic is optionally substituted with 1 or 2 groups selected from halogen, C0-C3 alkylalcohol, C0-C3 alkylamine, C0-C3 alkylCOOH, C0-C3 alkylCONH2, and C0-C3 alkylcyano.
6. A compound compound according to claim 1 wherein p is 1, R3a and R3b are both hydrogen and R4 is NR4aR4b; wherein R4b is 3,5-bistrifluoromethylbenzyl and R4a is selected from the group consisting of:
wherein each R is independently selected from the group consisting of: halogen, C0-C6 alkylalcohol, hydrogen, C1-C6 alkyl, C1-C6 alkoxy C0-C6 alkylcycloalkyl, C0-C6 alkylheterocyclic, C1-C6 alkylCN, C1-C6 haloalkyl, C0-C6 alkylNR11R12, C1-C6 alkylC(O)NR11R12, and C1-C6 alkylC(O)OR11.
7. A compound selected from the group consisting of:
(S)-5-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepine-1-carboxylic acid tetrahydro-pyran-4-yl ester,
(S)-2-{5-(3,5-Bis-trifluoromethyl-benzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4, 5-tetrahydro-1H-benzobazepin-5-yl)-amino-tetrazol-2-yl}-ethanol,
(S)-2-{5-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-yl}-ethanol,
(+\u2212)-9-(3,5-Bis-trifluoromethyl-benzyl)-(2H-tetrazol-5-yl)-amino-2,2-difluoro-6,7,8,9-tetrahydro-1,3-dioxa-5-aza-cycloheptafindene-5-carboxylic acid isopropyl ester,
(+\u2212)-Isopropyl 5-(3,5-bistrifluoromethyl-benzyl)-(1H-tetrazol-5-yl)-amino-8-chloro-2,3,4, 5-tetrahydrobenzobazepine-1-carboxylate,
(+\u2212)-isopropyl 5-(3,5-bistrifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-8-chloro-2,3,4,5-tetrahydrobenzobazepine-1-carboxylate,
(+\u2212) isopropyl -6-(3,5-bistrifluoromethyl-benzyl)-(1H-tetrazol-5-yl)-amino-2,3,6,7,8,9-hexahydro-1H-10-aza-cycloheptaeindene-10-carboxylate,
(+\u2212)-isopropyl 5-(3,5-bistrifluoromethyl-benzyl)-(5-methyl-1H-pyrazol-3-yl)-amino-8-chloro-2,3,4,5-tetrahydrobenzobazepine-1-carboxylate,
+\u2212)-isopropyl 5-(3,5-bistrifluoromethyl-benzyl)-(5-methyl-isoxazol-5-yl)-amino-8-chloro-2,3,4,5-tetrahydrobenzobazepine-1-carboxylate,)
(S)-6-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-21-1-tetrazol-5-yl)-amino-4-methyl-2,3,6,7,8,9-hexahydro-1H-10-aza-cycloheptaeindene-10-carboxylic acid isopropyl ester,
(S)-isopropyl 5-(3,5-bistrifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-8,9-dimethyl-2,3,4,5-tetrahydrobenzobazepine-1-carboxylate,
(S)-isopropyl 5-{(3,5-Bis-trifluoromethyl-benzyl)-2-(2-hydroxy-ethyl)-2H-tetrazol-5-yl-amino}-8,9-dimethyl-2,3,4,5-tetrahydrobenzobazepine-1-carboxylate,
(S)-9-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-2,3,6,7,8,9-hexahydro-1H-5-aza-cycloheptafindene-5-carboxylic acid tert-butyl ester,
(S)-(3,5-Bis-trifluoromethyl-benzyl)-(5-cyclopentylmethyl-1,2,3,5,6,7,8,9-octahydro-5-aza-cycloheptafinden-9-yl)-(2-methyl-2H-tetrazol-5-yl)-amine,
(S)-(3,5-Bis-trifluoromethyl-benzyl)-(5-cyclopentylmethyl-3,5,6,7,8,9-hexahydro-1H-2-oxa-5-aza-cycloheptafinden-9-yl)-(2-methyl-2H-tetrazol-5-yl)-amine,
(S)-5-{9-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-1,3,6,7,8,9-hexahydro-2-oxa-5-aza-cycloheptafinden-5-yl)-3,3-dimethyl-pentanoic acid,
(S)-5-(9-{(3,5-Bis-trifluoromethyl-benzyl)-2-(2-hydroxy-ethyl)-2H-tetrazol-5-yl-amino}-1,3,6,7,8,9-hexahydro-2-oxa-5-aza-cycloheptafinden-5-yl)-3,3-dimethyl-pentanoic acid,
(3,5-Bis-trifluoromethyl-benzyl)-(1-cyclopentylmethyl-2,3,4,5,7,8,9,10-octahydro-1H-naphtho2,3-bazepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)-amine,
(S)-6-{(3,5-Bis-trifluoromethyl-benzyl)-2-(2-hydroxy-ethyl)-2H-tetrazol-5-yl-amino)-2,3,6,7,8,9-hexahydro-1H-10-aza-cycloheptaeindene-10-carboxylic acid isopropyl ester,
(S)-6-{(3,5-Bis-trifluoromethyl-benzyl)-2-(2-hydroxy-ethyl)-2H-tetrazol-5-yl-amino}-4-methyl-2,3,6,7,8,9-hexahydro-1H-10-aza-cycloheptaeindene-10-carboxylic acid isopropyl ester,
(S)-9-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-2,3,6,7,8,9-hexahydro-1H-5-aza-cycloheptafindene-5,carboxylic acid 2-carboxy-2-methyl-propyl ester,
(S)-1-{5-(3,5-Bis-trifluoromethyl-benzyl)-2-methyl-2H-tetrazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-yl)-3-furan-2-ylmethoxy)-propan-2-one,
2-{5-(3,5-Bis-trifluoromethyl-benzyl)-2-methyl-2H-tetrazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-yl}-1-phenyl-ethanol,
2-{5-(3,5-Bis-trifluoromethyl-benzyl)-2-methyl-2H-tetrazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-yl) -2-phenyl-ethanol,
(4-{5-(3,5-Bis-trifluoromethyl-benzyl)-(3-methyl-isoxazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-ylmethyl}-cyclohexyl)-acetic acid methyl ester,
(4-{5-(3,5-Bis-trifluoromethyl-benzyl)-(3-methyl-isoxazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-ylmethyl}-cyclohexyl)-acetic acid,
(S)-(3,5-Bis-trifluoromethyl-benzyl)-(7-methyl-1-pyridin-4-ylmethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzobazepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)-amine,
(S)-(3,5-Bis-trifluoromethyl-benzyl)-(7-methyl-1-pyridin-4-ylmethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzobazepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)-amine hydrochloride,
(S)-(3,5-Bis-trifluoromethyl-benzyl)-(7-methyl-1-pyridin-3-ylmethyl-8-trifluoromethyl-2;3,4,5-tetrahydro-1H-benzobazepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)-amine,
(S)-2-{5-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-7-ethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-yl}-ethanol,
(S)5-{9-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-1,3,6,7,8,9-hexahydro-2-oxa-5-aza-cycloheptafinden-5-ylmethyl}-thiophene-2-carboxylic acid,
(S)-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-(5-pyridin-4-ylmethyl-3,5,6,7,8,9-hexahydro-1H-2-oxa-5-aza-cycloheptafinden-9-yl)-amine,
(S)-(4-{9-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-1,3,6,7,8,9-hexahydro-2-oxa-5-aza-cycloheptafinden-5-ylmethyl}-cyclohexyl)-acetic acid,
(S)-2-{9-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-1,3,6,7,8,9-hexahydro-2-oxa-5-aza-cycloheptafinden-5-yl}-ethanol,
(S)-9-2-(2-Amino-ethyl)-2H-tetrazol-5-yl-(3,5-bis-trifluoromethyl-benzyl)-amino-1,3,6,7,8,9-hexahydro-2-oxa-5-aza-cycloheptafindene-5-carboxylic acid tert-butyl ester,
(S)-2-(2-Amino-ethyl)-2H-tetrazol-5-yl-(5-benzyl-3,5,6,7,8,9-hexahydro-1H-2-oxa-5-aza-cycloheptafinden-9-yl)-(3,5-bis-trifluoromethyl-benzyl)-amine,
(S)-2-(2-Amino-ethyl)-2H-tetrazol-5-yl-(3,5-bis-trifluoromethyl-benzyl)-5-(3,3,3-trifluoro-propyl)-3,5,6,7,8,9-hexahydro-1H-2-oxa-5-aza-cycloheptafinden-9-yl-amine,
(S)-5-{5-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-2,3,4,5,7,8,9,10-octahydro-naphtho2,3-bazepin-1-yl}-3,3-dimethyl-pentanoic acid,
(S)-(3,5-Bis-trifluoromethyl-benzyl)-(1-cyclopentylmethyl-11-methyl-2,3,4,5,7,8,9,10-octahydro-1H-naphtho2,3-bazepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)-amine,
(S)-5-{5-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-ylmethyl}-thiophene-2-carboxylic acid,
(S)-(3,5-Bis-trifluoromethyl-benzyl)-(1,7-dimethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzobazepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)-amine,
(S)-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-(7-methyl-1-thiazol-2-ylmethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzobazepin-5-yl)-amine,
(S)-(3,5-Bis-trifluoromethyl-benzyl)-7-methyl-1-(1-methyl-1H-imidazol-2-ylmethyl)-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzobazepin-5-yl-(2-methyl-2H-tetrazol-5-amine,
(S)-5-{5-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-ylmethyl},
(S)-(3,5-Bis-trifluoromethyl-benzyl)-(7-methyl-1-piperidin-4-ylmethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzobazepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)-amine,
(S)-(4-{5-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-ylmethyl}-piperidin-1-yl)-acetic acid ethyl ester,
(S)-(4-{5-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-ylmethyl}-piperidin-1-yl)-acetic acid,
(S)-(3,5-Bis-trifluoromethyl-benzyl)-(7-methyl-1-pyrrolidin-2-ylmethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzobazepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)-amine,
(S)-2-(2-Amino-ethyl)-2H-tetrazol-5-yl-1-(2-benzyloxy-ethyl)-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzobazepin-5-yl-(3,5-bis-trifluoromethyl-benzyl)-amine,
(S)-2-{5-2-(2-Amino-ethyl)-2H-tetrazol-5-yl-(3,5-bis-trifluoromethyl-benzyl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-yl}-ethanol,
(S)-2-(2-Amino-ethyl)-2H-tetrazol-5-yl-(3,5-bis-trifluoromethyl-benzyl)-(7-methyl-1-thiazol-2-ylmethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzobazepin-5-yl)-amine,
(S)-(2-{5-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepin-1-yl}-ethoxy)-acetic acid,
(S)-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-7-methyl-1-(2H-tetrazol-5-ylmethyl)-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzobazepin-5-yl-amine,
(S)-5-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepine-1-carboxylic acid 2-amino-ethyl ester,
(S)-5-(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-amino-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-benzobazepine-1-carboxylic acid 2-carboxy-2-methyl-propyl ester,
(S)-2-(2-Amino-ethyl)-2H-tetrazol-5-yl-(3,5-bis-trifluoromethyl-benzyl)-(1-cyclopropylmethyl-7-methyl-8-tri fluoromethyl-2,3,4,5-tetrahydro-1H-benzobazepin-5-yl)-amine,
(S)-2-(2-Amino-ethyl)-2H-tetrazol-5-yl-(3,5-bis-trifluoromethyl-benzyl)-(1-cyclopropylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzobazepin-5-yl)-amine hydrochloride, and pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture of diastereomers thereof.
8. A method of modulating CETP activity comprising administering a therapeutically effective composition comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture of diastereomers thereof to a patient in need thereof.
9. The method of claim 8 wherein modulation of CETP activity results in a decrease in LDL-cholesterol.
10. A method of treating or preventing dyslipidemia comprising administering a therapeutically effective composition comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate diastereomer, mixture of diastereomers thereof, to a patient in need thereof.
11. A method of treating or preventing atherosclerosis comprising administering a therapeutically effective composition comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof to a patient.
12. A method of lowering plasma LDL-cholesterol in a mammal comprising administering a therapeutically effective dose of a compound of Formula I, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof to said mammal.
13. A method of treating andor preventing the pathological sequelae due to high levels of plasma LDL-cholesterol in a mammal comprising administering a therapeutically effective dose of a compound of Formula I, pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer, or mixture of diastereomers to said mammal.
14. A pharmaceutical composition comprising a compound according to claim 1 and at least one of: a carrier, diluent, and excipient.
15. Use of a compound according to claim 1 for the manufacture of a medicament for treating or preventing atherosclerosis in a mammal comprising administering an effective dose of a compound of Formula I, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate; diastereomer, or mixture of diastereomers thereof to said mammal.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A transit time ultrasound sensor for measuring a fluid flow in a conduit, comprising:
(a) a rigid housing;
(b) an upstream transducer affixed to the housing;
(c) a downstream transducer spaced from the upstream transducer and affixed to the housing to define an acoustic path between the upstream transducer and the downstream transducer, the acoustic path intersecting the fluid flow in the conduit; and
(d) a solid acoustic couplant disposed in the acoustic path and shaped to define a measuring channel sized to receive a length of the conduit, the acoustic couplant having an acoustic velocity within 10% of an acoustic velocity of the fluid flow and an acoustic velocity of the conduit wall, and an acoustic impedance within 10% of an acoustic impedance of the fluid flow and an acoustic impedance of the conduit wall.
2. A transit time ultrasound sensor for measuring a fluid flow in a conduit, comprising:
(a) a rigid housing;
(b) a first transducer affixed to the housing;
(c) one of a reflector and a second transducer spaced from the first transducer in one of an upstream location and a downstream location relative to the first transducer and affixed to the housing to define an acoustic path between the first transducer and the one of the reflector and the second transducer;
(d) a conduit in the acoustic path, the conduit having a curvilinear cross sectional profile, the transducer sized to illuminate the curved cross sectional profile with acoustic energy; and
(e) a solid acoustic couplant in the acoustic path and contacting the first transducer and at least partially defining a measuring channel sized to match the curvilinear conduit cross sectional profile.
3. A transit time ultrasound sensor for the measurement of fluid flow in a conduit, the sensor comprising:
(a) a rigid housing;
(b) a first transducer affixed to the housing for generating an acoustic wave having a nominal period and a planar wave front;
(c) a second transducer spaced from the first transducer and affixed to the housing to define an acoustic path between the first transducer and the second transducer along which the wave front travels to reach the second transducer;
(d) a conduit in the acoustic path having a curvilinear wall; and
(e) a solid acoustic couplant in the acoustic path and contacting a portion of the curvilinear wail; at least a portion of the planar wave front along the acoustic path reaching the second transducer within one-quarter of the nominal period.
4. A transit time ultrasound sensor as in claims 2 or 3, wherein the solid acoustic couplant contacts the first transducer.
5. The transit time ultrasound sensor of claim 1, wherein the solid acoustic couplant contacts the upstream transducer.
6. A transit time ultrasound sensor as in claims 1, 2 or 3, wherein the solid acoustic couplant is a plastic.
7. A transit time ultrasound sensor as in claims 1, 2 or 3, wherein the solid acoustic couplant is uncompressed.
8. A transit time ultrasound sensor as in claims 1, 2 or 3, wherein the solid acoustic couplant has an acoustic velocity within 5% of the acoustic velocity of the conduit.
9. A transit time ultrasound sensor as in claims 1, 2 or 3, wherein the solid acoustic couplant has an acoustic velocity within 5% of the acoustic velocity of the fluid flow.
10. A transit time ultrasound sensor as in claims 1, 2 or 3, wherein the solid acoustic couplant has an acoustic impedance within 5% of the acoustic impedance of the conduit.
11. A transit time ultrasound sensor as in claims 1, 2 or 3, wherein the solid acoustic couplant has an acoustic impedance within 5% of the acoustic impedance of the fluid flow.
12. A transit time ultrasound sensor as in claims 1, 2 or 3, wherein the solid acoustic couplant has a hardness between approximately 75 to 95 Shore A.
13. A transit time ultrasound sensor as in claims 1, 2 or 3, wherein the solid acoustic couplant encompasses at least 25% of a length of the acoustic path.
14. A transit time ultrasound sensor as in claims 1, 2 or 3, wherein the conduit is substantially free of deformation under contact with the solid acoustic couplant.
15. A transit time ultrasound sensor for measuring a fluid flow in a measuring channel having a channel wall, comprising:
(a) a rigid housing;
(b) a first transducer affixed to the housing; and
(c) a solid, resilient plastic acoustic couplant intermediate the first transducer and the measuring channel, the acoustic couplant having an acoustic velocity within 5% of an acoustic velocity of the fluid flow and an acoustic velocity of the channel wall, and the acoustic couplant having an acoustic impedance within 5% of an acoustic impedance of the fluid flow and an acoustic impedance of the channel wall, the first transducer defining an acoustic path.
16. The transit time ultrasound sensor of claim 15, wherein the acoustic couplant defines a portion of the measuring channel to have a curvilinear cross section.
17. The transit time ultrasound sensor of claim 15, wherein the acoustic couplant has a hardness between approximately 75 to 95 Shore A.
18. A transit time ultrasound sensor for the measurement of a blood flow in a conduit, the sensor configured with an acoustic path extending between an upstream location and a spaced apart downstream location, the acoustic path illuminating a blood flow in the conduit, the sensor comprising a solid acoustic couplant having a density between 0.9 gcm3 and 1.15 gcm3.
19. A transit time ultrasound sensor for the measurement of a blood flow in a conduit, the sensor configured with an acoustic path that illuminates a blood flow in the conduit, the sensor comprising a solid acoustic couplant having a density within 10% of a density of blood, an acoustic velocity within 10% of an acoustic velocity of blood and an acoustic impedance within 10% of an acoustic impedance of blood.
20. The transit time ultrasound sensor of claim 19, wherein the solid acoustic couplant is a plastic elastomer.
21. The transit time ultrasound sensor of claim 19, further comprising a transducer, wherein the transducer and the acoustic couplant illuminate a full field of the blood flow.
22. The transit time ultrasound sensor of claim 19, wherein the acoustic couplant has a curvilinear profile corresponding to a profile of a blood flow conduit.
23. The transit time ultrasound sensor of claim 19, wherein the acoustic couplant is one of a polyether block amide and a polyurethane.
24. A transit time ultrasound sensor for measuring a fluid flow, comprising:
(a) a frame;
(b) an upstream transducer connected to the frame;
(c) a downstream transducer spaced from the upstream transducer and connected to the frame; and
(d) a solid acoustic coupler disposed between the upstream transducer and the downstream transducer to define a measuring channel sized to receive a length of the conduit, the solid acoustic coupler having an acoustic velocity within 10% of an acoustic velocity of the fluid, an acoustic path defined between the upstream transducer and the downstream transducer.
25. The transit time ultrasound sensor of claim 24, wherein the solid acoustic coupler has an acoustic velocity within 10% of an acoustic velocity of a wall of the conduit.
26. The transit time ultrasound sensor of claim 24, wherein the solid acoustic coupler has an acoustic impedance within 10% of an acoustic impedance of the fluid.
27. The transit time ultrasound sensor of claim 24, wherein the solid acoustic coupler has an acoustic impedance within 10% of an acoustic impedance of a wall of the conduit.
28. The transit time ultrasound sensor of claim 24, wherein the solid acoustic coupler is a plastic.
29. The transit time ultrasound sensor of claim 24, wherein the solid acoustic coupler is a thermoplastic elastomer.
30. The transit time ultrasound sensor of claim 24, wherein the solid acoustic coupler is one of a polyether block amide and a polyurethane.